BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

849 related articles for article (PubMed ID: 22869151)

  • 21. JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin.
    Wang X; Liu Q; Ihsan A; Huang L; Dai M; Hao H; Cheng G; Liu Z; Wang Y; Yuan Z
    Toxicol Sci; 2012 Jun; 127(2):412-24. PubMed ID: 22454431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
    Oh ST; Gotlib J
    Expert Rev Hematol; 2010 Jun; 3(3):323-37. PubMed ID: 21082983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin-like growth factor-I receptor signal transduction and the Janus Kinase/Signal Transducer and Activator of Transcription (JAK-STAT) pathway.
    Himpe E; Kooijman R
    Biofactors; 2009; 35(1):76-81. PubMed ID: 19319849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.
    Vainchenker W; Dusa A; Constantinescu SN
    Semin Cell Dev Biol; 2008 Aug; 19(4):385-93. PubMed ID: 18682296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging targeted therapies in myelofibrosis.
    Barosi G
    Expert Rev Hematol; 2012 Jun; 5(3):313-24. PubMed ID: 22780211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancer of Polycomb and the Tip60 complex repress hematological tumor initiation by negatively regulating JAK/STAT pathway activity.
    Bailetti AA; Negrón-Piñeiro LJ; Dhruva V; Harsh S; Lu S; Bosula A; Bach EA
    Dis Model Mech; 2019 May; 12(5):. PubMed ID: 31072879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
    Yin LH; Zheng XQ; Li HY; Bi LX; Shi YF; Ye AF; Wu JB; Gao SM
    Leuk Res; 2015 Apr; 39(4):471-8. PubMed ID: 25666256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
    Smith CA; Fan G
    Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.
    Mughal TI; Girnius S; Rosen ST; Kumar S; Wiestner A; Abdel-Wahab O; Kiladjian JJ; Wilson WH; Van Etten RA
    Leuk Lymphoma; 2014 Sep; 55(9):1968-79. PubMed ID: 24206094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.
    Schwemmers S; Will B; Waller CF; Abdulkarim K; Johansson P; Andreasson B; Pahl HL
    Exp Hematol; 2007 Nov; 35(11):1695-703. PubMed ID: 17764814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
    Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
    Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAK-mutant myeloproliferative neoplasms.
    Levine RL
    Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of Janus kinases in haemopoiesis and haematological malignancy.
    Khwaja A
    Br J Haematol; 2006 Aug; 134(4):366-84. PubMed ID: 16822289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients.
    Irino T; Uemura M; Yamane H; Umemura S; Utsumi T; Kakazu N; Shirakawa T; Ito M; Suzuki T; Kinoshita K
    PLoS One; 2011; 6(7):e22148. PubMed ID: 21789226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamics and non-canonical aspects of JAK/STAT signalling.
    Mohr A; Chatain N; Domoszlai T; Rinis N; Sommerauer M; Vogt M; Müller-Newen G
    Eur J Cell Biol; 2012; 91(6-7):524-32. PubMed ID: 22018664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. JANUS under stress--role of JAK/STAT signaling pathway in vascular diseases.
    Grote K; Luchtefeld M; Schieffer B
    Vascul Pharmacol; 2005 Nov; 43(5):357-63. PubMed ID: 16271517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Janus Kinase-Signal Transducer and Activator of Transcription Inhibitors for the Treatment and Management of Cancer.
    Rizwi FA; Abubakar M; Puppala ER; Goyal A; Bhadrawamy CV; Naidu VGM; Roshan S; Tazneem B; Almalki WH; Subramaniyan V; Rawat S; Gupta G
    J Environ Pathol Toxicol Oncol; 2023; 42(4):15-29. PubMed ID: 37522565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engagement of the B-cell antigen receptor activates STAT through Lyn in a Jak-independent pathway.
    Wang L; Kurosaki T; Corey SJ
    Oncogene; 2007 May; 26(20):2851-9. PubMed ID: 17146444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JAK2 and MPL mutations in myeloproliferative neoplasms.
    Koppikar P; Levine RL
    Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systems biology of JAK/STAT signalling.
    Pfeifer AC; Timmer J; Klingmüller U
    Essays Biochem; 2008; 45():109-20. PubMed ID: 18793127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.